- Home
- HBT vs XERS Comparison
HBT vs XERS Comparison
Compare HBT & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBT | XERS |
|---|---|---|
| Founded | 1920 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 760.7M | 1.3B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HBT | XERS |
|---|---|---|
| Price | $26.44 | $7.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $28.63 | $10.43 |
| AVG Volume (30 Days) | 33.5K | ★ 2.1M |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | ★ 12.74 | N/A |
| EPS | ★ 2.48 | N/A |
| Revenue | $233,255,000.00 | ★ $266,137,000.00 |
| Revenue This Year | $9.02 | $44.37 |
| Revenue Next Year | $32.67 | $27.87 |
| P/E Ratio | $10.63 | ★ N/A |
| Revenue Growth | 6.87 | ★ 42.05 |
| 52 Week Low | $19.46 | $3.14 |
| 52 Week High | $27.02 | $10.08 |
Technical Indicators
Market Signals| Indicator | HBT | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 71.49 | 47.42 |
| Support Level | $24.19 | $6.85 |
| Resistance Level | $25.22 | $7.24 |
| Average True Range (ATR) | 0.64 | 0.29 |
| MACD | 0.29 | 0.09 |
| Stochastic Oscillator | 95.65 | 84.94 |
Price Performance
Historical ComparisonAbout HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).